Loading... Please wait...

Our Newsletter

LY2886721 | BACE inhibitor

  • LY2886721.jpg
  • LY2886721, 400x400px, png
Catalog #:

Product Description

LY2886721 is an orally-available, furothiazine-based inhibitor of b-amyloid protein cleaving enzyme (BACE) for the treatment of Alzheimer's disease. [1] It inhibits recombinant hBACE1 with an IC50 of 20 nM. [2] In cellular assays, LY2886721 inhibits Abeta with an IC50 range of 10-19 nM. Oral administration of LY2886721 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99, and sAPPbeta. [2]

Technical information:

Chemical Formula:   C18H16F2N4O2S
CAS #:   1262036-50-9
Molecular Weight:   390.41
Purity:   > 98%
Appearance:   White
Chemical Name:   N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide
Solubility:   Up to 20 mM in DMSO
Synonyms:   LY-2886721, LY 2886721, LY2886721

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Alzheimer's Disease Research Unit Studies synopsis (April 1, 2012)
2. Alzheimer Assocation International Conference, 2012, Oral Sessions (O1-06-03): "Preclinical Characterization of LY2886721: A BACE1 inhibitor in clinical developmetn for early Alzheimer's disease"

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the LY2886721 | BACE inhibitor to your wish list.

You Recently Viewed...